03rd week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220016081 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 - Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects | 2022-01-20 |
20220016082 | COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS - Provided herein are methods of treating high and very high risk MDS comprising administering pracinostat and a DNA hypomethylating agent. S | 2022-01-20 |
20220016083 | METHODS OF TREATING CANCERS - The present invention relates to methods and compositions for the treatment of BAF-related disorders such as melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematologic cancer. | 2022-01-20 |
20220016084 | COMPOUNDS FOR TREATING LYMPHOMA OR A T-CELL MALIGNANT DISEASE - The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patients platelet count. | 2022-01-20 |
20220016085 | COMPOUNDS FOR TREATING MULTIPLE MYELOMA - The invention relates to tinostamustine for use in the treatment of multiple myeloma. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. The present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count. | 2022-01-20 |
20220016086 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES - Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. | 2022-01-20 |
20220016087 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF NAPROXEN SODIUM AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY OF HEARTBURN AND/OR THE RISK OF HEARTBURN - Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking naproxen sodium for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) naproxen sodium at a dosage from about 100 mg to about 440 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of naproxen sodium in the unit oral dose composition in said human at the same specified time. | 2022-01-20 |
20220016088 | UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN AND FAMOTIDINE FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN - Described herein are unit oral dose compositions that reduce the severity of heartburn and/or the risk of the occurrence of heartburn in a human in need of taking ibuprofen for the OTC treatment of acute pain wherein the human is not experiencing heartburn prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen at a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen in the unit oral dose composition in said human at the same specified time. | 2022-01-20 |
20220016089 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE - Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions. | 2022-01-20 |
20220016090 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER - Provided is a novel method for treating cancer using an HSP90 inhibitor which exhibits a markedly superior antitumor effect and has a reduced side effect. | 2022-01-20 |
20220016091 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA - Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof. | 2022-01-20 |
20220016092 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES - This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy. This includes supranuclear gaze palsies, including horizontal and vertical saccadic gaze palsies, and cognitive deficits or gait disorders, such as in a patient having Gaucher disease or Niemann-Pick disease Type C. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. | 2022-01-20 |
20220016093 | Compositions for Aiding Liver Function - The disclosure relates to compositions that promote liver health. The disclosure also relates to compositions that prevent, mitigate, relieve or reduce the symptoms of hangover. | 2022-01-20 |
20220016094 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2022-01-20 |
20220016095 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETH- YL)ACETAMIDE - This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal. | 2022-01-20 |
20220016096 | GEL CONTAINING PIRFENIDONE - The invention relates to a gel composition containing pirfenidone, which is advantageous over other cutaneously administered pharmaceutical forms known in the prior art and which can be used in treatment for the restoration of tissues with fibrotic lesions and for the prevention of fibrotic lesions. | 2022-01-20 |
20220016097 | 1,4-DIHYDROPYRIDINE COMPOSITIONS, METHODS OF MAKING AND USE - Provided herein are pharmaceutical compositions comprising a class of calcium channel blockers and at least one chelating agent. More specifically, the pharmaceutical compositions comprise at least one 1,4-dihydropyridine (DHP) compound and at least one chelating agent. The chelating agents used in this disclosure can decrease the degradation of the constituent DHPs of the DHP compositions. The DHP compositions can be used to treat cardiovascular disorders and are more stable for prolonged periods of time. | 2022-01-20 |
20220016098 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING SAME - The present invention relates to an orally administered pharmaceutical composition comprising Fab I inhibitors, and to a method for preparing same. The present invention may be applied effectively to bacterial infections resistant to antibiotics and the like. More specifically, the present invention can more rapidly initiate therapeutic effects by improving dissolution and elution rates. Furthermore, the present invention can improve the mixing and content uniformity in preparations by regulating the particle size. | 2022-01-20 |
20220016099 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF - The present invention provides a pharmaceutical composition for preventing and treating central nervous system (CNS) diseases, diabetes and complications thereof, the pharmaceutical composition comprising, as an active ingredient, a benzimidazole or benzoxazole derivative having the structure of chemical formula 1 or a pharmaceutically acceptable salt thereof. The benzimidazole or benzoxazole derivative used as an active ingredient in the pharmaceutical composition of the present invention can, via an Nrf2 activation mechanism caused by the Keap1-Nrf2-ARE pathway and via an activation pathway of glutamate transporters such as GLT-1/EAAT and GLAST, inhibit oxidative damage in the central nervous system and the pancreas while inducing production of an antioxidant such as glutathione, thereby maximizing the effect of treating central nervous system diseases, diabetes and complications thereof. | 2022-01-20 |
20220016100 | Treatment of Hearing Loss by Inhibition of Casein Kinase 1 - Methods for treating hearing loss that include administering an inhibitor, e.g., a small molecule inhibitor, of casein kinase 1, preferably in combination with a treatment that stimulates Atoh1 gene expression, e.g., a gamma-secretase inhibitor, an Atoh1 stimulatory compound, or a GSK-3-beta inhibitor. | 2022-01-20 |
20220016102 | ER PROTEIN REGULATORS AND USE THEREOF - The present disclosure relates to an ER protein regulator compound represented by formula (I) and use thereof. LIN in the compound represented by formula (I) is a linker; ULM is a small-molecule ligand of VHL or CRBN protease having a ubiquitylation function; and group X is CH | 2022-01-20 |
20220016103 | METHODS OF USING FACTOR B INHIBITORS - Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride. | 2022-01-20 |
20220016104 | COMPOSITIONS AND METHODS FOR TREATING DEPRESSION - Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants. | 2022-01-20 |
20220016105 | BIASED NMDA RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that can be capable of modulating an N-methyl-D-aspartate (NMDA) receptor. In some embodiments, the compound(s) can be a biased modulator of an NMDA receptor. In some embodiments, the compound(s) can be a biased allosteric modulator of an NMDA receptor. Also described herein are methods of treating an NMDA-mediated disease by administering one or more of the compounds described herein. In some embodiments, the compounds can be effective to treat a neurobiological or psychiatric disease or disorder. | 2022-01-20 |
20220016106 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS - The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2′-fluoro-[1,1′-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid). | 2022-01-20 |
20220016107 | PHARMACEUTICAL COMPOSITIONS - The invention provides (+)-α-dihydrotetrabenazine succinate salt. | 2022-01-20 |
20220016108 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE - Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes. | 2022-01-20 |
20220016109 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE - The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized. | 2022-01-20 |
20220016110 | COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME - The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals. | 2022-01-20 |
20220016111 | Methods of Treating Inflammation - Methods for treating inflammation, including allergic inflammation, lymphocyte-driven inflammation, and inflammatory conditions such as allergic asthma and allergic lung inflammation, using inhibitors of the polycomb repressive complex 2 (PRC2) methyltransferase enhancer of zeste homolog 2 (Ezh2) are provided. | 2022-01-20 |
20220016112 | DIHYDROQUINOXALINE AND DIHYDROPYRIDOPYRAZINE DERIVATIVES AS RSV INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2022-01-20 |
20220016113 | ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA - (alpha-2C) antagonists, in particular substituted piperidinyl-pyrimidinyl-tetra hydrochinolines and piperidinyl-pyridinyl-tetrahydrochinolines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which X is a group (A) or (B). | 2022-01-20 |
20220016114 | Heart Rate Decreasing Agent - The present invention addresses the problem of providing an agent for decreasing heart rate having fewer side effects, or a novel agent for suppressing an increase in heart rate during exercise. The heart rate can be decreased, in particular, palpitation, shortness of breath or fatigue associated with an increased heart rate can be prevented or ameliorated, and the increase in heart rate during exercise can be suppressed by ingesting a preparation containing orotic acid or a salt thereof as an active ingredient. | 2022-01-20 |
20220016115 | USP19 INHIBITORS FOR USE IN THERAPY - Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy. | 2022-01-20 |
20220016116 | DETERMINING DRUG COMBINATIONS, SYNERGISTIC DRUG COMBINATION AND USE THEREOF IN PANCREATIC CANCER TREATMENT - A method for determining combination drug and use in pancreatic cancer treatment, includes retrieving Pancreatic cancer datasets from a plurality of data sources based on selected types of expression profiling. A set of feature genes is determined based on differential gene expression analysis of disease samples and control samples in normalized pancreatic cancer datasets. Pancreatic cancer targets are selected for combination analysis based on druggability and determined set of feature genes. Based on node embedded clustering of the selected pancreatic cancer targets, synergistic target pairs is determined. Candidate pairs of drug combinations are selected from a plurality of pairs of drug combinations based on cumulative ranking score of each pair of drug combination and the synergistic target pairs. Based on prioritization of candidate pairs of drug combinations, filtration of drug combinations of epidermal growth factor receptor inhibitor, and external validation, one or more sets of drug combinations are determined. | 2022-01-20 |
20220016117 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor. | 2022-01-20 |
20220016118 | COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF - A combination of
| 2022-01-20 |
20220016120 | METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS - Embodiments of the present invention are directed to formulations and methods of treating folic acid deficiency and morning sickness. The dosage form has an effective amount, of a folic add with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis. | 2022-01-20 |
20220016121 | CRYSTALLINE SODIUM SALT OF 5-METHYL-(6S)-TETRAHYDROLIC ACID - The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same. | 2022-01-20 |
20220016122 | SALT OF N-(2,6-DIETHYLPHENYL)-8-({4-[4-(DIMETHYLAMINO) PIPERIDIN-1-YL]-2-METHOXYPHENYL}AMINO)-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4- ,3-h]QUINAZOLINE-3-CARBOXAMIDE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT - N-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): | 2022-01-20 |
20220016123 | PHOSPHOINOSITIDE 3-KINASE AND SRC INHIBITORS FOR TREATMENT OF PANCREATIC CANCER - A phosphoinositide 3-kinase inhibitor for use in the treatment of pancreatic cancer and a method for treatment of pancreatic cancer including administration of an phosphoinositide 3-kinase inhibitor an Src inhibitor to a human subject in need thereof. There is also provided a pharmaceutical composition comprising a phosphoinositide 3-kinase inhibitor and an Src inhibitor. | 2022-01-20 |
20220016124 | ANTI-VIRAL COMPOSITIONS - A solid or semi-solid state anti-viral lip balm composition comprising a direct or indirect nucleoside analog inhibitor of herpes simplex viral DNA polymerase or a pharmaceutically acceptable salt thereof mixed with at least one wax, at least one carrier oil selected from the group consisting of coconut oil including refined coconut oil and sunflower oil and a butter or butter substitute as a softening agent. | 2022-01-20 |
20220016125 | RIBOFLAVIN FOR TREATING COLLAGENOUS TISSUES IN THE DISEASES OF JOINTS, PARTICULARLY OF INVERTEBRAL DISCS - Riboflavin for use as a medicament in the treatment of a patient with a disease of a diarthrotic, amphiarthrotic or synarthrotic joint, preferably an intervertebral disc disease is provided. The treatment occurs in situ in the patient and includes local administering of riboflavin in a collagenous tissue of the joint and subsequent irradiation with electromagnetic radiation. A method and a kit are also provided for carrying out in-situ crosslinking of a collagenous tissue in the case of a disease of a diarthrotic, amphiarthrotic or synarthrotic joint, preferably an intervertebral disc. | 2022-01-20 |
20220016126 | PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETO - Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed. | 2022-01-20 |
20220016127 | COMPOSITIONS AND METHODS FOR INDUCING APPENDAGE AND LIMB REGENERATION - Disclosed herein include methods, compositions, and kits suitable for use in inducing reparative regeneration and/or appendage regeneration. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of one or more amino acids and a therapeutically effective amount of one or more sugars, and thereby inducing reparative regeneration or appendage regeneration in the subject. There are provided, in some embodiments, regenerative agents suitable for use in the methods provided herein. Regenerative agents can stimulate mTOR signaling and/or insulin signaling. Regenerative agents can include one or more amino acids, insulin, and/or one or more sugars. | 2022-01-20 |
20220016128 | METHODS, SYSTEM, AND KIT FOR MONITORING, DIAGNOSING, AND TREATING IMPULSIVE AGGRESSION - The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems. | 2022-01-20 |
20220016129 | USE OF HOMOHARRINGTONINE IN PREPARATION OF BETACORONAVIRUS REPLICATION INHIBITOR IN HUMAN - Disclosed is a use of homoharringtonine (HHT) in preparation of a drug against betacoronavirus infection, a use of homoharringtonine in preparation of a betacoronavirus replication inhibitor in human, and a formulation and a method for treating a disease caused by betacoronavirus. Through research, the HHT is found to not only have a good inhibitory effect on the first step of protein synthesis, but also have an unexpected inhibitory effect on each step of protein synthesis elongation, and can better inhibit the synthesis of long proteins. Because betacoronaviruses have longer ORFs and are more sensitive to the HHT, the HHT has a better replication inhibition effect on the betacoronaviruses, thus providing a feasible solution for controlling the replication of coronaviruses. The effects of the HHT on treating diseases caused by the betacoronaviruses including SARS-CoV-2 are confirmed for the first time by cell experiments and animal models. | 2022-01-20 |
20220016130 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS - This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering (a) one or more AKT inhibitors and/or one or more CDK inhibitors and/or one or more CBP/p300 inhibitors in combination with (b) one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT, CDK, and CBP/p300 inhibitors are provided. | 2022-01-20 |
20220016131 | METHODS FOR IMPROVED TREATMENT OF CANCER - Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors. | 2022-01-20 |
20220016132 | BISMUTH-THIOLS AS ANTISEPTICS FOR BIOMEDICAL USES, INCLUDING TREATMENT OF BACTERIAL BIOFILMS AND OTHER USES - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. | 2022-01-20 |
20220016133 | VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS - Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD). | 2022-01-20 |
20220016134 | COMPOSITIONS AND METHODS FOR THE TOPICAL ADMINISTRATION OF SPIRONOLACTONE FOR THE TREATMENT OF CUTANEOUS SIGNS OF EXCESS ANDROGEN AND CHRONIC STRESS RESPONSE - The present disclosure provides methods for treating or alleviating symptoms of a disease, disorder, or condition related to excess androgen or stress-induced skin changes in a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Other aspects relate to methods for providing anti-oxidative stress, anti-inflammatory and anti-aging benefits for the skin to a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Surprisingly, it has been found that spironolactone may be topically administered with reduced adverse effect compared to systemic administration of the same medication. | 2022-01-20 |
20220016135 | TREATING BREAST CANCER WITH HORMONE RECEPTOR MODULATORS - The invention provides a classification and treatment system for breast cancer using measurements of and ligands for estrogen receptor, androgen receptor, vitamin D receptor, and optionally HER2 receptor. | 2022-01-20 |
20220016136 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS - The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. | 2022-01-20 |
20220016137 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION - The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms. | 2022-01-20 |
20220016138 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF - The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVII). | 2022-01-20 |
20220016139 | METHODS OF INHIBITING HIV INFECTIONS BY PRE-EXPOSURE PROPHYLAXIS - A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation. | 2022-01-20 |
20220016140 | INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYLAXIS - A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation. | 2022-01-20 |
20220016141 | METHODS OF PREVENTING HIV INFECTIONS IN HUMANS - A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation. | 2022-01-20 |
20220016142 | COMBINATION THERAPY FOR TREATMENT OF CANCER - The present invention relates to the treatment of cancer using a combination of (a) a NK inhibitor (b) a checkpoint inhibitor. | 2022-01-20 |
20220016143 | INHIBITORS OF ARG1 AND/OR ARG2 - Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein. | 2022-01-20 |
20220016144 | STABLE AQUEOUS COMPOSITION COMPRISING OLIGOSACCHARIDES - The present invention concerns a stable aqueous composition comprising oligosaccharides having a glucose unit at the reducing end and characterised in that the pH of such aqueous composition ranges from 5.5 to 6.5.5 | 2022-01-20 |
20220016145 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS - The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders. | 2022-01-20 |
20220016146 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION - Provided herein are compounds/compositions that are useful for killing or inhibiting the growth of a microorganism, such as | 2022-01-20 |
20220016147 | APPLICATION OF CHIDAMIDE IN COMBINATION WITH R-CHOP, AND DRUG COMBINATION - The present application provides an application of Chidamide in combination with R-CHOP in preparing a drug used for treating B-cell lymphoma, and also provides a drug comprising Chidamide and R-CHOP. Chidamide in combination with R-CHOP has a synergistic therapeutic effect on B-cell lymphoma. | 2022-01-20 |
20220016148 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY - Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG). | 2022-01-20 |
20220016149 | METHOD OF PREVENTING DIARRHOEA - The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travellers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal. | 2022-01-20 |
20220016150 | SUSTAINED RELEASE OF ANTIINFECTIVES - Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both. | 2022-01-20 |
20220016151 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING - The present approach effectively eradicates senescent cells and cells carrying the hallmarks associated with aging, through inhibiting mitochondrial biogenesis during induced mitochondrial oxidative stress, without inhibiting normal cells. Embodiments may include a therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, a therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and a therapeutic agent that behaves as a pro-oxidant or induces mitochondrial oxidative stress. Some embodiments include sub-antimicrobial antibiotic concentrations, thereby minimizing antibiotic resistance concerns. | 2022-01-20 |
20220016152 | IMMUNE MODULATORY COMBINATIONS AND METHODS FOR TREATING CANCERS - The presently disclosed embodiments relate to immune modulatory compositions and methods for treating cancers using combination therapy. | 2022-01-20 |
20220016153 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO - This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds. | 2022-01-20 |
20220016154 | TREATMENT OF NEURONAL MOSAICISM IN DEMENTIA - A method for the use of at least one reverse transcriptase inhibitor, that when administered in a safe and effective amount, ameliorate at least one of the formation, maintenance, or expression of excessive neuronal mosaicism, and therefore decrease or block neurogenic mechanisms underlying or associated with dementia. | 2022-01-20 |
20220016155 | Composition for Inhibiting Replication of Hepatitis B Virus - The present invention provides a pharmaceutical composition for treating hepatitis B. The present invention provides a composition for inhibiting the replication of hepatitis B virus and a pharmaceutical composition for treating hepatitis B virus infection, each comprising an inhibitory substance against microRNA binding to the 5′ epsilon signal sequence in the pregenomic RNA of hepatitis B virus. | 2022-01-20 |
20220016156 | RNAI MOLECULE FOR TREATING CANCER - An RNAi molecule for cancer treatment, including the nucleotide sequence of SEQ ID NO: 1 in an antisense strand; and a method for treating a cancer, including administering an effective amount of the RNAi molecule to a subject in need thereof. The antisense strand includes the nucleotide sequence selected from SEQ ID NOs: 11-30. | 2022-01-20 |
20220016157 | METHOD FOR PREVENTING ORAL CANCER - Disclosed are a method for preventing and treating oral cancer with an exosome carrying miR-185, and a pharmaceutical composition which contains a modified salivary exosome and is used for preventing and treating oral cancer. | 2022-01-20 |
20220016158 | METHOD OF ADMINISTRATION AND TREATMENT - Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein. | 2022-01-20 |
20220016159 | METHOD OF ADMINISTRATION AND TREATMENT - Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein. | 2022-01-20 |
20220016160 | METHOD FOR PREVENTING OR TREATING INFECTION OF RESPIRATORY VIRUS UTILIZING GOLD NANOPARTICLES - A method of treating or preventing infection of a respiratory virus, includes administering to a subject a composition comprising gold nanoparticles, where the gold nanoparticles serve to hinder morphological change of protein of the virus and block entry of the virus into human cells. The gold nanoparticles in the composition are in form of negatively-charged gold colloidal solution. The composition further comprises an S1 proteolysis inhibitor. The gold nanoparticles each have a diameter of 0.1 nm to 100 nm. | 2022-01-20 |
20220016161 | IRON-FORTIFIED FOOD COMPOSITION - The present invention relates to compositions for fortifying food and/or beverages with iron. More specifically, the present invention relates to compositions comprising Fe(III), phytic acid, a hydrolysed protein and an acidity regulator, which provide stable and soluble sources of iron for fortifying food and/or beverages. | 2022-01-20 |
20220016162 | COMPOSITIONS AND METHODS FOR TREATING BONE INJURY - The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2. | 2022-01-20 |
20220016163 | DENDRITIC HUMAN UNIVERSAL NON-ANTIGEN EDUCAP VACCINE - A non-antigenic microRNA exosomal vaccination that includes dendritic-derived exosomes resulting from the incubation of dendritic cells with Spike Protein of a COVID-19 virus so that the dendritic cells process the Spike Protein of the COVID-19 virus to enable education of naïve T-cells. The exosomes so-derived are then harvested and encapsulated for delayed release oral capsule delivery to selectively reach intestinal antigen-presenting cells in the terminal ileum for stimulating an acquired immune response to the Spike Protein of the COVID-19 virus. The intestinal antigen-presenting cells incorporate the dendritic-derived exosomes, and thereby learn to recognize the Spike Protein as a threat, even though no dangerous antigens, RNA, or DNA modifications of the antigen or Spike Protein of the COVID-19 virus were introduced by the non-antigenic microRNA exosomal vaccine, thereby avoiding creation of new pandemic viral emergencies, cytokine storms, mitochondrial aerobic failure, serious illnesses, and death via mutated strains of the COVID-19 virus. | 2022-01-20 |
20220016164 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF PANCREATIC CANCER - The present invention relates to a method for the treatment of pancreatic cancer comprising administering to a patient in need thereof a CD40 agonist in combination with dendritic cells loaded with a lysate of mesothelioma cells. A further aspect of the present invention relates to dendritic cells loaded with a lysate of mesothelioma cells for use in the treatment of pancreatic cancer. A last aspect of the present invention relates to a pharmaceutical composition comprising such loaded dendritic cells. | 2022-01-20 |
20220016165 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY - The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient. | 2022-01-20 |
20220016166 | T-CELL EXPRESSING CHIMERIC RECEPTOR - Provided is a T-cell expressing a chimeric receptor, wherein the chimeric receptor specifically recognizes BCMA, and the endogenous TCR molecule and the endogenous MHC molecule are silenced. Also provided is the use of the T-cell in the preparation of a drug for treating BCMA positive tumors. | 2022-01-20 |
20220016167 | T-Rapa Cells as Novel Effector Cell Type for Chimeric Antigen Receptor Therapy - The present disclosure provides chimeric antigen receptor (CAR)-T-Rapa cells and methods of making and using them. Specifically, methods of producing T-Rapa cells that can express chimeric antigen receptors is provided. | 2022-01-20 |
20220016168 | METHODS OF USING CD27 ANTIBODIES AS CONDITIONING TREATMENT FOR ADOPTIVE CELL THERAPY - Methods of performing adoptive immunotherapy comprising administering to patients a CD27 antibody in combination with an adoptive immunotherapy (e.g., genetically modified autogenous and allogenous T-cells) are provided. | 2022-01-20 |
20220016169 | NRF-2 DEFICIENT CELLS AND USES THEREOF - The present disclosure relates to T cell anticancer immunotherapy based on modulation of Nrf2 expression, that is, to an Nrf2-targeting immune cell, e.g., T cell, anticancer therapy. The present disclosure allows deep interference with the Nrf2 expression in T cells, thereby solving the problem of immune tolerance shown by cancer cells to T cells; in other words, the effect of anticancer immunotherapy can be improved by targeting Nrf2. The present disclosure can provide an Nrf2-targeting new T cell anticancer immunotherapy and a T cell for the second-generation anticancer immunotherapy. This technology is applicable to the preparation of CAR-T, engineered T, and TIL T cells, and to the treatment of various solid carcinomas, including lymphoma. It can be said to be a new anticancer therapy that improves the therapeutic efficacy effectively. | 2022-01-20 |
20220016170 | CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 2022-01-20 |
20220016171 | MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS - The present invention relates generally to immunotherapy, in particular immunotherapy for treating cancer, infectious diseases or autoimmune diseases. More specifically, the invention relates to Mucosal-Associated Invariant T (MAIT) cells expressing Chimeric Antigen Receptors (CARs), wherein the MAIT cell is allogenic with respect to the subject to be treated. | 2022-01-20 |
20220016172 | ACTIVATION OF MARROW INFILTRATING LYMPHOCYTES IN HYPOXIC ALTERNATING WITH NORMOXIC CONDITIONS - In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs. | 2022-01-20 |
20220016173 | GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE - A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts. | 2022-01-20 |
20220016174 | FOETAL MESENCHYMAL STEM CELL COMPOSITION OF ALLOGENIC ORGIN, TREATMENT METHOD AND USE THEREOF IN MASTITIS IN MILK-PRODUCING ANIMALS, INCLUDING CATTLE - The present invention relates to the use of regenerative medicine in livestock farming, in particular to regenerative medicine for the care of livestock, and even more particularly to regenerative medicine in the care of milk-producing animals, including cattle. Specifically, the invention concerns a foetal mesenchymal stem cell (MSC) composition of allogenic origin, a treatment method and the use thereof in mastitis in milk-producing animals, including cattle, suffering from mastitis, to immunostimulate the animal, the MSC coming from foetal bovine adipose tissue. The composition can be administered via the intramammary route, exercising an immunomodulatory effect on the inflammatory response and strengthening antimicrobial activity against mastitis-causing pathogens in milk-producing animals with mastitis, thereby becoming an alternative to replacing and/or supplementing the use of antibiotics. | 2022-01-20 |
20220016175 | STEM CELL-DERIVED EXTRACELLULAR VESICLES AND METHODS OF USE THEREOF - Disclosed herein are bionanoparticles of adipose-derived stem cell extracellular vesicles, a tissue repair matrix comprising the bionanoparticles, and methods of use thereof for enhanced tendon healing. | 2022-01-20 |
20220016176 | DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS - The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed. | 2022-01-20 |
20220016177 | UNIVERSAL DONOR CELLS - Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor. | 2022-01-20 |
20220016178 | Generation Of Uniform Hepatocytes From Human Embryonic Stem Cells By Inhibiting TGF-BETA and Methods Of Maintaining Hepatic Cultures - This disclosure relates generally to new methods of maintaining the expression of hepatic genes in human hepatocytes and method for maintaining the functional hepatic enzyme activity of primary hepatocytes in culture. The disclosure also encompasses new methods of deriving a population of pure hepatocytes without selecting or sorting the cells from the cultured pluripotent cells. | 2022-01-20 |
20220016179 | Amniotic Membrane Hydrogel and Methods of Making - The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta. In certain embodiments, the composition comprises amniotic membrane powder or solubilized amniotic membrane (SAM). In some aspects, the composition is cell-free and rich in cytokines, extracellular matrix proteins, and other components that improve tissue regeneration. In one aspect, the composition is a hydrogel scaffold that comprises amniotic membrane. The present invention reduces contraction and improves blood vessel development in regenerating tissue. | 2022-01-20 |
20220016180 | UMBILICAL TISSUE COMPOSITIONS AND METHODS OF USE - Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. | 2022-01-20 |
20220016181 | IMMUNOMODULATORY CELLS AND USES THEREOF - Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen. | 2022-01-20 |
20220016182 | ASCAROSIDE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES - The present invention relates to the use of ascr#7 for preventing or treating IL-6 and/or IL-1β-mediated diseases. | 2022-01-20 |